Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.
The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.47 Decreased by -147.37% | -0.49 Increased by +4.08% |
| Feb 26, 24 | -0.45 Increased by +22.41% | -0.52 Increased by +13.46% |
| Nov 8, 23 | -0.46 Increased by +46.51% | -0.57 Increased by +19.30% |
| Aug 8, 23 | -0.54 Increased by +31.65% | -0.59 Increased by +8.47% |
| May 3, 23 | -0.19 Increased by +72.06% | -0.62 Increased by +69.35% |
| Feb 28, 23 | -0.58 Increased by +19.44% | -0.86 Increased by +32.56% |
| Nov 3, 22 | -0.86 Decreased by -91.11% | -0.89 Increased by +3.37% |
| Aug 3, 22 | -0.79 Decreased by -36.21% | -0.83 Increased by +4.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.94 M Decreased by -87.02% | -45.17 M Increased by +44.05% | Decreased by -2.32 K% Decreased by -331.15% |
| Jun 30, 23 | 933.00 K Decreased by -94.97% | -52.76 M Increased by +23.66% | Decreased by -5.65 K% Decreased by -1.42 K% |
| Mar 31, 23 | 58.98 M Increased by +220.30% | -9.17 M Increased by +83.89% | Decreased by -15.55% Increased by +94.97% |
| Dec 31, 22 | 44.36 M Increased by +159.89% | -48.31 M Increased by +29.60% | Decreased by -108.91% Increased by +72.91% |
| Sep 30, 22 | 14.98 M Increased by +5.31% | -80.73 M Decreased by -86.42% | Decreased by -538.92% Decreased by -77.01% |
| Jun 30, 22 | 18.55 M Increased by +38.30% | -69.10 M Decreased by -25.34% | Decreased by -372.53% Increased by +9.38% |
| Mar 31, 22 | 18.41 M Increased by +65.27% | -56.91 M Decreased by -26.22% | Decreased by -309.07% Increased by +23.62% |
| Dec 31, 21 | 17.07 M Increased by +7.37% | -68.62 M Decreased by -29.20% | Decreased by -402.07% Decreased by -20.34% |